Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Status:	Completed
Conditions:	HIV / AIDS
Therapuetic Areas:	Immunology / Infectious Diseases
Healthy:	No
Age Range:	18 - 55
Updated:	4/17/2018
Start Date:	March 22, 2010
End Date:	May 19, 2014

Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462

The purpose of this long-term follow-up study is to assess the long-term health status of
HIV-infected subjects who previously participated in GSK-sponsored trials evaluating the
investigational HIV vaccine 732462. This study will provide additional data concerning the
long-term benefits/risks associated with vaccination.

No vaccine will be administered during the study period. Vaccines were administered during
the primary studies.

General information on the health of the subject and persistence of the cellular and humoral
immune responses to study vaccination will be evaluated.

Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

- HIV-infected subject.

- Previous participation in a study evaluating GSK HIV vaccine 732462.

- Written informed consent obtained from the subject.

Exclusion Criteria:

The following criteria should be checked at the time of study entry. If ANY exclusion
criterion applies, the subject must not be included in the study:

• Subjects who did not receive a complete vaccination course in previous studies.

We found this trial at

sites

GSK Investigational Site

Annandale, Virginia 22003

from

Annandale, VA